Table 2. Summary of 6 randomized controlled trials included in the meta-analysis.
| Study (yr) | Patients | Geographic region | Intervention/Comparator | OS | DFS | LRR | Toxicities |
|---|---|---|---|---|---|---|---|
| Park et al. (2021) [11] | Curatively D2-resected stage II–III, node-positive GC (n=546) | Korea | CRT (SOXRT, n=183), CA (SOX, n=181), CA (S-1, n=182) | Not reported | At 3 years: CRT (SOXRT, 72.8%), CA (SOX, 74.3%), CA (S-1, 64.8%) | Not reported | All toxicities: CRT (SOXRT, 60%), CA (SOX, 70%), CA (S-1, 69%) |
| Cats et al. (2016) [12] | Stage IB–IVA resectable gastric or GE AD after perioperative chemotherapy and surgery (n=788) | Netherlands, Sweden, Denmark | CRT (XPRT, n=395), CA (EXP or EXO, n=393) | At 5 years: CRT (40%), CA (42%) | At 5 years: CRT (38%), CA (39%) | CRT: 11.2% (27/241), CA: 15.0% (35/233) | Gr ≥3 toxicities: XPRT: 45% (111/245), EXP or EXO: 57% (135/233) |
| Lee et al. (2012) [14] | Curatively D2-resected stage IB–IVA GC (n=788) | Korea | CRT (XPRT, n=230), CA (XP, n=228) | At 5 years: CRT (75%), CA (73%) | At 3 years: XPRT (78.2%), XP (74.2%) | CRT: 6.5% (15/230), CA: 12.7% (29/228) | Treatment modification: XPRT: 35% (80/230), XP: 52% (119/228) |
| Kim et al. (2012) [43] | Curatively D2-resected stage II–IVA GC (n=90) | Korea | CRT (FLRT, n=46), CA (FL, n=44) | At 5 years: CRT (65.2%), CA (54.6%) | At 5 years: CRT (60.9%), CA (50.0%) | CRT: 10.9% (5/46), CA: 23.3% (7/30) | Hematologic and GI toxicities: CRT 19.6% and 17.4% (8/46), FL 25% and 11.4% (5/44) |
| Zhu et al. (2012) [44] | Curatively D2-resected stage II–IVA GC (n=351) | China | CRT (FLRT, n=186), CA (FL, n=165) | At 5 years: CRT (48.4%), CA (41.8%) | At 5 years: CRT (45.2%), CA (35.8%) | CRT:15.6% (29/186), CA: 24.2% (40/165) | GI toxicities: CRT: 5.9% (11/186), CA: 0.0% (0/165) |
| Kwon et al. (2010) [42] | Curatively D2-resected stage II–IVA GC (n=61) | Korea | CRT (XRT, n=31), CA (FP, n=30) | At 5 years: CRT (70.1%), CA (70.0%) | At 5 years: CRT (76.7%), CA (59.1%) | CRT: 12.9% (4/31), CA: 23.3% (7/30) | GI toxicities: CRT: 9.7% (3/31), CA: 13.3% (4/30) |
OS = overall survival; DFS = disease-free survival; LRR = locoregional recurrence; GC = gastric cancer; CRT = chemoradiotherapy; SOXRT = S-1 plus oxaliplatin and S-1 and radiotherapy; CA = chemotherapy alone; SOX = S-1 plus oxaliplatin; GE AD = gastro-oesophageal adenocarcinoma; XPRT = capecitabine plus cisplatin with radiotherapy; EXP or EXO = epirubicin + cisplatin or oxaliplatin + capecitabine; XP = capecitabine plus cisplatin; FLRT = fluorouracil plus leucovorin with radiotherapy; FL = fluorouracil plus leucovorin GI = gastrointestinal.